Monday, July 03, 2017

Add Academy to ECW or other EMR to send orders for Sleep & EEG Testing Outpatient for Kids and Adults in Texas

Dear Colleague,

Sleep referrals are complex these days.

·      Home sleep test?  In-Lab Test?
·      Adult patients fail with home tests.
·      Patients fail home AUTO CPAP.

For 10 years Academy and its physician experts have welcomed infants and children of all ages & complexity.   Our affiliated Houston AND San Antonio  specialists can be seen HERE.

What can you do for your patients and to make the office flow smoothly?

Optimize your EMR function by adding Academy Diagnostics:


  • ·      Academy Diagnostics will help your patients and your practice access gold-standard care.
  • ·      Academy can save you and your MA time.

In eClinicalWorks  or another EMR, add Academy Diagnostics to seamlessly refer your sleep and EEG procedures via P2P or other systems, by the following:

1)   Add us to your Referring providers

a.     Last Name = Academy
b.    First Name = Diagnostics
c.     Specialty = Sleep Medicine


Academy Diagnostics - Houston

Academy Diagnostics – San Antonio

7505 FANNIN ST
HOUSTON, TX 77054

Phone: 832-659-0248
 Fax: 832-659-0261


8215 FREDERICKSBURG RD
SAN ANTONIO, TX  78229-3355

Phone: 210-616-9500
Fax: 210-616-0400

NPI: 1093112518

NPI: 1861615163


Taxonomy 261QS1200X

Taxonomy 261QS1200X


2)    You can also:


  •     create other custom specialties and entries for special procedures: EEG lab, e.g. neurophysiology.
  •        add Academy under “Labs” if this works well for your workflow.


Please notify us if you have questions about procedure codes.

Our PDF of order forms can be found HERE

Academy Diagnostics Staff



 Illustration of Linked Procedures  - (Sleep and EEG/Neuro)

-->

PEDIATRIC SLEEP PROCEDURES (under 6) Newborns can have sleep studies by day. 

o 95782 Pediatric Diagnostic Polysomnogram (Sleep Study)
o 95783 Pediatric CPAP Titration (If Polysomnogram is positive for OSA or a previous study was performed and results are available)

PEDIATRIC Over 6 Years AND ADULT SLEEP PROCEDURES
o 95810 Diagnostic Polysomnogram (Sleep Study) (HST if required by insurance)
o 95811 CPAP Titration (If polysomnogram is positive for OSA or a previous study was performed and results are available.)
o 95811 Split Night Study (Treatment portion to be performed only if the patient meets criteria.)
o 95805 Multiple Sleep Latency Test (MSLT) following a Diagnostic Polysomnogram
o 95805 Maintenance of Wakefulness Test (MWT)

HOME Sleep Testing - Adults

o 
oCPT Code 95806 Sleep study, unattended, simultaneous recording of heart rate, oxygen saturation, respiratory airflow and respiratory effort.
 
  oHCPCS Code  G0399 Home sleep test with Type III portable monitor, unattended; minimum of four channels: two respiratory movement/airflow, one ECG/heart rate and one oxygen saturation

Sample Linked DIAGNOSIS Must indicate at least one qualifying diagnosis:
o G47.33 Obstructive Sleep Apnea
o G47.37 Central Sleep Apnea
o E66.01 Obesity Hypoventilation Syndrome
o G47.61 Periodic Limb Movement Disorder
o F51.8 Sleep Related Movement Disorders, unspecifed
o G47.419 Narcolepsy
o F51.13 Organic Hypersomnia/EDS
o G47.54 Parasomnias
o G47.20 Disruption of 24 hr Sleep/Wake Cycle Other Qualifying Code ___________________


PRE-TEST ESSENTIAL Data for Adults  PRE-EXISTING CONDITIONS NOTE: Please indicate if the following Are Applicable

o E66.01 Morbid Obesity (Needs additional diagnosis)
o Pulmonary Disease (Respiratory Failure, COPD, Hypoxemia) 
oNeurologic OR Neuromuscular Disease (Epilepsy, Dementia, ALS, Parkinson’s, etc.)
o Significant Cardiac Disease (CHF, Atrial Fibrillation, Pulmonary Hypertension, Arrhythmias) 
oAll other conditions  ______________________

PRE-Test Essential Data for Adults

Ht:________________ Wt:________________ Neck Circumference________ BMI_________
*Epworth Sleepiness Scale (ESS = 10 or more)






Neuro-Diagnostics - EEG

o Routine EEG (Greater than one hour)
o Extended Video EEG Monitoring (Greater than 14 hours)

Sample Diagnoses:
R40.4 Transient alteration of awareness
R55 Syncope and collapse
G40.389 Epilepsy, unspecified
R56.9 Other Convulsions (e.g. seizure NOS)
R56 Convulsions






-->

Tuesday, June 13, 2017

Avie Grunspan MD - Academy Diagnostics Congratulates American Academy Sleep Medicine Fellow

What a well-deserved honor! 


AASM congratulates New Fellow members

American Academy of Sleep Medicine
American Academy of Sleep Medicine
Friday, May 19, 2017


Fellow status in the AASM is a unique honor that recognizes special competency in sleep medicine and significant contributions to the field. The AASM is pleased to welcome the following new Fellow members:
  • Avie Grunspan, MD, FAASM


Access Care Here Serving San Antonio, Seguin, New Braunfels 

Wednesday, May 31, 2017

CBD and Epilepsy Seizures - A New Study

Image result for cannabidiolThis is a study of a pharmaceutical grade pill going through FDA approval. This is NOT a study of nutritional CBD.

The study observed a 22% reduction in seizures. 5% were seizure free. This will be a welcome addition, to therapy.

I always remind parents to watch this literature AND to watch reports of side effects of the agent.

This agent is NOT available in Texas.  CBD is not available from a Texas source at this time. Tough situation for kids- JR


Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome

Orrin Devinsky, M.D., J. Helen Cross, Ph.D., F.R.C.P.C.H., Linda Laux, M.D., Eric Marsh, M.D., Ian Miller, M.D., Rima Nabbout, M.D., Ingrid E. Scheffer, M.B., B.S., Ph.D., Elizabeth A. Thiele, M.D., Ph.D., and Stephen Wright, M.D., for the Cannabidiol in Dravet Syndrome Study Group*

N Engl J Med 2017; 376:2011-2020May 25, 2017DOI: 10.1056/NEJMoa1611618

BACKGROUND

The Dravet syndrome is a complex childhood epilepsy disorder that is associated with drug-resistant seizures and a high mortality rate. We studied cannabidiol for the treatment of drug-resistant seizures in the Dravet syndrome.

CONCLUSIONS

Among patients with the Dravet syndrome, cannabidiol resulted in a greater reduction in convulsive-seizure frequency than placebo and was associated with higher rates of adverse events. 

Preview Article HERE